Technology | September 28, 2012

Boston Scientific Launches Emerge PTCA Balloon Dilatation Catheter in the U.S.

Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions

September 28, 2012 — Boston Scientific Corp. announced it has received U.S. Food and Drug Administration (FDA) clearance for the Emerge percutaneous transluminal coronary angioplasty (PTCA) balloon dilatation catheter, and has begun marketing the device in the United States. The Emerge catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability for physicians to address challenging lesions in coronary arteries. Both monorail and over-the-wire (OTW) options are available. The Emerge catheter has been commercially available in CE mark countries since earlier this year.

"The Emerge balloon catheter combines Boston Scientific's innovative balloon technologies into a single platform," said J. Tift Mann, III, M.D., Wake Heart and Vascular, Raleigh, N.C.  "The result is exceptional deliverability and reliable performance in a wide range of anatomy and lesion types."

The Emerge balloon catheter is available in a wide array of balloon diameters from 1.5 mm up to 4.0 mm, with balloon lengths ranging from 8 mm up to 30 mm. Both the monorail and OTW catheters are available with two distinct shaft technologies designed to provide versatility in addressing different clinical situations. The "Push Technology" (1.5 mm) offers a single-segment inner shaft for enhanced pushability. The "Workhorse Technology" (1.5 mm to 4.0 mm) features a bi-segment inner shaft designed for excellent deliverability without sacrificing push.

"Boston Scientific is committed to delivering innovative technology that enables physicians to improve outcomes for patients undergoing coronary interventions," said Kevin Ballinger, president of the Interventional Cardiology Division at Boston Scientific.  "The Emerge balloon catheter further enhances the Boston Scientific portfolio by offering a versatile platform with a range of options and features that allow physicians to select the appropriate balloon based on clinical need."

Coronary artery disease represents the leading cause of death in the United States, accounting for more than 870,000 deaths each year. PTCA balloon dilatation catheters are used in coronary angioplasty and stenting procedures to open arteries blocked by atherosclerosis, which if left untreated can cause angina and heart attack.

For more information: www.bostonscientific.com

Related Content

Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init